Working… Menu

A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma (PHILEMON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02460276
Recruitment Status : Completed
First Posted : June 2, 2015
Last Update Posted : April 24, 2020
Janssen, LP
Nordic Lymphoma Group
Information provided by (Responsible Party):
Lund University Hospital